CHEMICAL SENSITIVITY
Kay derides clinical ecology generally, but particularly its concept of chemical sensitivity, which he considers absurd. Yet clinical ecology actually overlaps the conventional. Innumerable papers on toxicology show that humans can be harmed by xenobiotic chemicals. With specific reference to allergy, Davies has recently shown that urban pollutants stimulate sensitisation.? Polyaromatic hydrocarbon levels similar to those commonly encountered can depress lymphocyte function.3 Sulphur dioxide, common in motor exhaust fumes, can trigger asthma attacks. 4 There is also growing evidence that reactions to foods and chemical substances can be related to enzyme pathways. Food induced migraine has been linked to low sulphoxidation. 5 Reduced cytochrome P450 activity increases the toxicity of many substances, 6 and there is evidence linking genetic differences in debrisoquine hydroxylation to the risk of Parlinson's disease.7 This last link explains correlations between geographical variations in Parkinson's disease and pesticide exposure. 8 Kay is critical of the provocation-neutralisation technique. I particularly object to his quoting in his BMJ article the review of the method included in the report of the Royal College of Physicians9 without making it plain that he was one of its primary coauthors.
Provocation-neutralisation is an empirical method, but there are several papers which support it. I cite three examples here: the definitive two part, multicentre, triple blind crossover study by King et al, "I which showed the correlation of oral challenge feeding to provocation (poor) and to neutralisation (good) separately; a-1984 paper by Rea et a, which showed effective neutralisation of symptoms on ingestion of foods12; and one from Scadding and Brostoff using resistance to nasal challenge with housedust mite."' These all point to an effect which cannot be ignored.
The reason for so much of the controversy is that all the papers said to be against provocation-neutralisation investigated only the supposed ability of the method accurately to provoke symptoms. This has never been claimed, and I admit that it is a controversial idea. Most often quoted of these negative studies was continue to use whatever treatment we see fit. I am grateful to the General Medical Council for opposing the attempt to unseat me. Their "inaction" was not a failure but a positive step towards defending that freedom. The use of metformin in non-insulin diabetic patients with renal failure is contraindicated because of the risk of developing lactic acidosis. The condition is fatal in up to 80% ofthese patients. We report a case ofacidosis in a woman started on metformin when her renal function was normal but whose treatment was not stopped when renal failure developed.
Case report A 76 year old woman with non-insulin dependent diabetes was started on continuous ambulatory peritoneal dialysis in 1991 for end stage renal failure. In 1987 she had been started on metformin in the diabetic clinic. Her serum creatinine concentration at that time was normal (<110 ,mol/). In October 1990 she developed complete heart block after a myocardial infarction and a permanent pacemaker was implanted.
She was admitted on 1 January 1993 with a 24 hour history of general debility and drowsiness. She was taking nifedipine 40 mg, metformin 1000 mg, thyroxine 0 05 mg, and calcium carbonate 1500 mg daily in divided doses. Her dialysis regimen comprised four 2 litre exchanges (2x3 86% and 2x1-36%) daily. She had not taken aspirin or alcohol. On examination her breath was acidotic and she had hypotension (90/50 mm Hg), hypothermia with a rectal temperature of 34-5°C, and a paced cardiac rhythm. Arterial blood gas concentrations on 24% oxygen were oxygen 22-3 kP, carbon dioxide 1-6 kP. Results of other relevant investigations were pH 6- In view of severe hypotension and myocardial depression she was not given haemodialysis. Despite these measures she became comatose, her acidosis remained refractory, and she died 20 hours after admission.
Discussion
Prompted by this case we examined the use of metformin in patients with renal impairment. We found that in Grampian metformin had been used in 13 out of 28 patients with non-insulin dependent diabetes who had a serum creatinine concentration above 300 (range 301-1062) ,mol/ during 1 July 1989 to 30 June 1990 and which did not return to normal over the subsequent two years (or till death, whichever occurred first). During this period metformin was stopped in five patients. One further patient continued to be given metformin as he refused treatment with insulin.
This case and our survey highlight two important considerations in managing diabetic patients with renal impairment. Firstly, it is essential to consider stopping metformin if the patient develops renal failure or myocardial ischaemia. Our patient was started on metformin when her renal function was normal but unfortunately this was overlooked when renal failure developed. Our survey of renal failure showed that metformin is often given to patients with renal failure. We may have underestimated the use of metformin in renal impairment as we examined only patients with a serum creatinine concentration of 300 ,umol/l or above.
Secondly, it is important to recognise that lactate is used as buffer in almost all currently available peritoneal dialysate solutions. Lactate is absorbed at a rate of 25 mEq/hour throughout 24 hours of peritoneal dialysis,2 so dialysis with lactate buffer must be stopped whenever lactic acidosis is suspected. Lactate dehydrogenase catalyses the conversion of lactate to
